GENFIT: ANNUAL GENERAL MEETING VOTE RESULTS

All resolutions adopted in accordance with the Management Board’s recommendations

Lille (France), Cambridge (Massachusetts, United States), July 1st, 2010 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the results of voting at its Annual General Meeting held on June 24th, 2010 in Lille (France). During this meeting, the annual reports as well as the corporate and consolidated financial statements for the 2009 financial year were endorsed by 99.81% of the votes cast.

The register of participating shareholders showed that 9,910,606 of a total of 11,622,166 shares were represented. Accordingly, 85.27% of the company’s total share capital was represented.

The results of voting on the resolutions proposed by the Management Board were as follows:

FIRST RESOLUTION:
Approval of annual reports and financial statements for the year ending December 31, 2009: resolution endorsed by 99.81% of cast votes. Of the votes cast, 17,972,320 voted for, 35,000 voted against, and no abstention.

SECOND RESOLUTION:
Approval of reports and consolidated financial statements for the year ending December 31, 2009: resolution endorsed by 99.81% of cast votes. Of the votes cast, 17,972,320 voted for, 35,000 voted against, and no abstention.

THIRD RESOLUTION:
Profit allocation for the year ending December 31, 2009: resolution adopted unanimously.

FOURTH RESOLUTION:
Approval of regulated agreements covered by the special Auditor’s report: resolution adopted unanimously.

FIFTH RESOLUTION:
Reading of the special report of the Management Board on options for shares subscription in accordance with Article L. 225-184 of the Commercial Law: resolution endorsed by 99.31% of cast votes. Of the votes cast, 17,882,320 voted for, 125,000 voted against, and no abstention.

SIXTH RESOLUTION:
Reading of the special report of the Management Board on the award of bonus shares in accordance with Article L. 225-197-4 of the Commercial Law: resolution endorsed by 99.31% of cast votes. Of the votes cast, 17,882,320 voted for, 125,000 voted against, and no abstention.

SEVENTH RESOLUTION:
Reading of the complementary report of the Management Board on the delegation of powers and authority granted to it by the General Assembly in accordance with Articles L. 225-129-1 and following of the Commercial Law: resolution adopted unanimously.
EIGHTH RESOLUTION:
Reading of the complementary report of the Management Board on the use of the delegation of powers granted by the General Assembly in accordance with Article R.225-116 of the Commercial Law: resolution endorsed by 99.31 % of cast votes. Of the votes cast, 17,882,320 voted for, 125,000 voted against, and no abstention.

NINTH RESOLUTION:
Appointment of a new Supervisory Board Member to replace a resigning member: resolution endorsed by 99.81 % of cast votes. Of the votes cast, 17,972,320 voted for, 35,000 voted against, and no abstention.

TENTH RESOLUTION:
Allocation of attendance fees: resolution endorsed by 99.99 % of cast votes. Of the votes cast, 18,007,170 voted for, 0 voted against, and there were 150 abstentions.

ELEVENTH RESOLUTION:
Formality powers: resolution adopted unanimously.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in strategic therapeutic fields linked to cardiometabolic and neurodegenerative disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, Alzheimer’s...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health concerns and their unmet medical needs. GENFIT’s proprietary research programs and its partnerships with leading pharmaceutical companies, including SANOFI-AVENTIS, SOLVAY GROUP, and SERVIER, have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development. GENFIT’s lead proprietary compound, GFT505, is currently in Phase II and two other compounds, in partnership with SANOFI-AVENTIS and SOLVAY, are in the advanced stages of Phase I.
With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 120 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT
Jean-François Mouney – Chairman of the Management Board
+33 (0)3 2016 4000

MILESTONES – Press Relations
Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr